Brigatinib Crystalline Forms for NSCLC Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ALK-positive non-small cell lung cancer (NSCLC) face challenges due to drug resistance, necessitating the development of new therapies and a better understanding of the polymorphic forms of active pharmaceutical ingredients like brigatinib to ensure consistent manufacturing and stability.
Innovation Solution
Identification and characterization of novel crystalline forms of brigatinib, including Forms A, B, C, D, E, F, G, H, J, and K, which are suitable for pharmaceutical formulation, providing methods for their preparation and use in treating NSCLC and other conditions responsive to protein kinase inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If multiple polymorphic forms of brigatinib are identified and characterized, then the stability and consistency of the pharmaceutical formulation are improved, but the complexity of manufacturing and quality control increases
Solution Approach 1:
The patent applies parameter changes by systematically varying crystallization conditions (solvent type, temperature, pH, concentration) to obtain different polymorphic forms of brigatinib. Each polymorph is characterized by specific physical parameters (XRPD patterns, melting point, solubility) that define its stability profile. This allows selection of the most stable polymorph for pharmaceutical formulation while understanding the conditions required to maintain that stability.
Solution Approach 2:
The patent performs preliminary characterization of all possible polymorphic forms before final formulation selection. By预先 identifying and characterizing Forms A through K, including their stability profiles, solubility, and transformation conditions, the patent enables informed selection of the optimal polymorph for manufacturing, thereby avoiding later stability issues while maintaining manageable complexity through upfront research.
2Manufacturing precision
If the polymorphic forms are fully characterized for pharmaceutical development, then the manufacturing precision and drug quality are improved, but the time and resources required for development increase
Solution Approach 1:
The patent performs comprehensive preliminary characterization of all polymorphic forms (Forms A-K) including XRPD patterns, melting points, solubility, and stability profiles before final formulation selection. This upfront research establishes clear selection criteria and manufacturing parameters, enabling precise reproduction of the chosen polymorph while avoiding time-consuming troubleshooting later in development.
Solution Approach 2:
The patent uses high-throughput screening methods and automated characterization techniques that can rapidly assess multiple polymorphic forms. By employing efficient analytical methods and systematic screening approaches, the patent minimizes the time and resources required for full characterization while still obtaining all necessary data for manufacturing precision.
3Reliability
If novel crystalline forms are developed to improve solubility and bioavailability, then the therapeutic efficacy is improved, but the difficulty of detecting and measuring the correct polymorph increases
Solution Approach 1:
The patent establishes distinct physical parameters for each polymorphic form, particularly XRPD diffraction patterns at specific 2θ angles, melting points, and solubility characteristics. These parameter definitions create clear fingerprint profiles for each form, making detection and identification straightforward through standard analytical techniques despite the presence of multiple polymorphs.
Solution Approach 2:
The patent employs X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) as objective, automated analytical methods to identify and quantify polymorphic forms. These instrumental methods replace subjective visual inspection or simple physical tests, providing rapid, accurate, and unambiguous detection of the correct polymorph even in complex formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The characterization of these crystalline forms enhances the stability, solubility, and bioavailability of brigatinib, addressing resistance issues and improving treatment outcomes for ALK-positive cancers by ensuring consistent drug quality and efficacy.
Implementation Method 1
X-ray powder diffraction patterns
Implementation Method 2
X-ray powder diffraction patterns
Implementation Method 3
differential scanning calorimetry
Implementation Method 4
solubility, and bioavailability of brigatinib
Implementation Method 5
dissolution rate
Data Source
AI summary
Novel crystalline forms of brigatinib, pharmaceutical compositions comprising the same, and methods of their preparation and use of the same are disclosed herein.